Newsfeeds Archive - Page 13 of 56

2 minute read

Red Light Holland’s Q1 2024 Performance: Revenue Soars 53% And Solid Cash Balance

August 29, 3:28 PM

Ontario-based mushrooms producer Red Light Holland Corp. (OTCQB: TRUFF) filed its quarterly financial statements, management discussion and analysis for the three months ended June 30. The Numbers:

TRUFF

2 minute read

Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M

By Lara Goldstein

August 29, 2:31 PM

Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9 (CA$43.3) million.

CYBN

4 minute read

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player’s Retreat, Fellini’s LSD Creativity, Surveys, Financing & More

By Lara Goldstein

August 28, 4:07 PM

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

ATAI

2 minute read

Cybin’s Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

By Lara Goldstein

August 28, 1:38 PM

Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o

CYBN

2 minute read

Funding The Future Of Psychedelics: Cybin Launches Renewed ATM Equity Program Up To $35M

By Lara Goldstein

August 24, 3:49 PM

Psychedelics biotech Cybin Inc. (NYSE: CYBN) announced it has renewed its previously established at-the-market (ATM) equity program allowing the company to gradually issue and sell up to $35 million in common shares to the public through appointed agents Cantor Fitzgerald Canada Corp.

CYBN

2 minute read

GH Research Psychedelics Firm Q2 2023 Repots $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026

By Lara Goldstein

August 24, 3:03 PM

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading psychedelics stocks listed in Nasdaq, shared its financial results and business updates for its second quarter en

GHRS

2 minute read

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

By Lara Goldstein

August 23, 8:09 PM

Starting this October, scientists at Imperial College London’s (ICL) Centre for Psychedelic Research will assess psilocybin-assisted therapy for gambling addiction, noted Psychedelic Spotlight.

FLHLF

3 minute read

Psyched: Fed Study On Psychedelics, Janet Yellen’s Magic Mushrooms, Financing Deals & Quarterly Reports

By Lara Goldstein

August 21, 10:55 AM

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

ATAI

2 minute read

Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library

By Lara Goldstein

August 16, 3:16 PM

Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs

CYBN

2 minute read

$21.8M Revenue For NASDAQ-Listed Psychedelics Ancillary Company Societal CDMO’s Q2 2023

By Lara Goldstein

August 16, 3:00 PM

Societal CDMO Inc. (NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for small molecule therapeutics, reported financial results for the three and six months ended June 30, 2023.

SCTL